- Erika F Duffell1, Dagmar Hedrich2, Otilia Mardh1, Antons Mozalevskis3
-
View Affiliations Hide AffiliationsAffiliations: 1 European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden 2 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal 3 WHO Regional Office for Europe, Copenhagen, DenmarkErika F DuffellErika.Duffell ecdc.europa.eu
-
View Citation Hide Citation
Citation style for this article: Duffell Erika F, Hedrich Dagmar, Mardh Otilia, Mozalevskis Antons. Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions. Euro Surveill. 2017;22(9):pii=30476. https://doi.org/10.2807/1560-7917.ES.2017.22.9.30476 Received: 23 Jun 2016; Accepted: 09 Nov 2016
Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions
Abstract
The World Health Organization ‘Global Health Sector Strategy on Viral Hepatitis 2016–2021’ aimed at the elimination of viral hepatitis as a public health threat provides a significant opportunity to increase efforts for tackling the epidemics of hepatitis B and hepatitis C virus infections across Europe. To support the implementation and monitoring of this strategy, core epidemiological and programmatic indicators have been proposed necessitating specific surveys, the systematic collection of programmatic data and the establishment of monitoring across the care pathway. European Union and European Economic Area countries already made progress in recent years implementing primary and secondary prevention measures. Indeed, harm reduction measures among people who inject drugs reach many of those who need them and most countries have a universal hepatitis B vaccination programme with high coverage above 95%. However, while a further scaling up of prevention interventions will impact on incidence of new infections, treating those already infected is necessary to achieve reductions in mortality. The epidemiological, demographic and socio-political situation in Europe is complex, and considerable diversity in the programmatic responses to the hepatitis epidemic exists. Comprehension of such issues alongside collaboration between key organisations and countries will underpin any chance of successfully eliminating hepatitis.

Article metrics loading...

-
From This Site
/content/10.2807/1560-7917.ES.2017.22.9.30476dcterms_title,dcterms_subject,pub_keyword105 -
PubMed
-
Google Scholar

Full text loading...
References
-
European Centre for Disease Prevention and Control (ECDC). Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC. Nov 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/systematic-review-hepatitis-B-C-prevalence.pdf
-
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593-608. https://doi.org/10.1016/j.jhep.2012.12.005 PMID: 23419824
-
Dultz G, Zeuzem S. Hepatitis C. A European perspective. Gastroenterol Clin North Am. 2015;44(4):807-24. https://doi.org/10.1016/j.gtc.2015.07.008 PMID: 26600221
-
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. https://doi.org/10.1016/S0140-6736(14)61682-2 PMID: 25530442
-
World Health Organization (WHO). Combating Hepatitis B and C to reach elimination by 2030. Geneva: WHO; May 2016. Available from: http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf?ua=1
-
World Health Organization (WHO). Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Geneva: WHO; 2016. Available from: http://apps.who.int/iris/bitstream/10665/204790/1/9789241510288_eng.pdf
-
World Health Organization Regional Office for Europe (WHO/Europe). Action plan for the health sector response to viral hepatitis in the WHO European Region. Copenhagen: WHO/Europe; Sep 2016. Available from: http://www.euro.who.int/__data/assets/pdf_file/0008/315917/66wd10e_HepatitisActionPlan_160555.pdf?ua=1
-
Duffell EF, Mozalevskis A, Mardh O, Hedrich D. Monitoring the WHO recommended core indicators for viral hepatitis B and C in EU/EEA Member States: supporting the global vision of elimination. Poster session presented at: International Liver Congress of the European Association for the Study of the Liver; Barcelona, Spain. 13-17 Apr 2016.
-
Duffell EF, van de Laar MJ. Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009. Euro Surveill. 2015;20(13):17-24. https://doi.org/10.2807/1560-7917.ES2015.20.13.21080 PMID: 25860392
-
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug-related infectious diseases in Europe: update from the EMCDDA expert network, November 2016. Lisbon: EMCDDA; 2016. Available from: http://www.emcdda.europa.eu/publications/rapid-communications/2016/drug-related-infectious-diseases-in-europe
-
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Hepatitis C among drug users in Europe. Epidemiology, treatment and prevention. Lisbon: EMCDDA; 2016. Available from: http://www.emcdda.europa.eu/system/files/publications/2953/TDXD16002ENN_final_web.pdf
-
Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46(Suppl 5):S158-64. https://doi.org/10.1016/j.dld.2014.09.023 PMID: 25453870
-
Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. . Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9(7):e103345. https://doi.org/10.1371/journal.pone.0103345 PMID: 25068274
-
European Centre for Disease Prevention and Control (ECDC). Epidemiological assessment of hepatitis B and C prevalence among migrants in the EU/EEA. Stockholm: ECDC; Jul 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/epidemiological-assessment-hepatitis-B-and-C-among-migrants-EU-EEA.pdf
-
Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88(7):558-64. PMID: 22859499
-
European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2016. Hepatitis B. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/healthtopics/hepatitis_B/Documents/aer2016/AER-hepatitis-B.pdf
-
de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190-200. https://doi.org/10.1002/hep.27969 PMID: 26146815
-
World Health Organization (WHO). Immunization, Vaccines and Biologicals. Data, statistics and graphics. Geneva: WHO; [Accessed 22 Jun 2016]. Available from: http://www.who.int/immunization/monitoring_surveillance/data/en/
-
European Centre for Disease Prevention and Control (ECDC). Vaccine Schedule. Stockholm: ECDC. [Accessed 24 May 2016]. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
-
European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2016. Hepatitis C. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/healthtopics/hepatitis_C/Documents/aer2016/AER-hepatitis-C.pdf
-
Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011;18(Suppl 1):1-16. https://doi.org/10.1111/j.1365-2893.2011.01499.x PMID: 21824223
-
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2016: Trends and Developments. Lisbon: EMCDDA; May 2016. Available from: http://www.emcdda.europa.eu/publications/edr/trends-developments/2016
-
European Union (EU). EU Drugs Strategy (2013 – 20). Off J Eur Union. 2012;C 402/01. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52012XG1229(01)&from=EN
-
Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol. 2013;19(40):6703-9. https://doi.org/10.3748/wjg.v19.i40.6703 PMID: 24187444
-
Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10(1):7. https://doi.org/10.1186/1477-7517-10-7 PMID: 23651646
-
Seedat F, Hargreaves S, Friedland JS. Engaging new migrants in infectious disease screening: a qualitative semi-structured interview study of UK migrant community health-care leads. PLoS One. 2014;9(10):e108261. https://doi.org/10.1371/journal.pone.0108261 PMID: 25330079
-
European Commission. Crisis Preparedness and Response. Joint Procurement of medical countermeasures. Brussels: European Commission. [Accessed 14 Jun 2016]. Available from: http://ec.europa.eu/health/preparedness_response/joint_procurement/index_en.htm
-
World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO; Mar 2015. Available from: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1
-
World Health Organization (WHO). Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version. Geneva: WHO; Apr 2016. http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1.
-
World Health Organization (WHO). Manual for the development and assessment of national viral hepatitis plans: a provisional document. Geneva: WHO; Sep 2015. Available from: http://apps.who.int/iris/bitstream/10665/183726/1/9789241509350_eng.pdf
-
Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16(12):1409-22. PMID: 27615026

Data & Media loading...
